Shares of AbbVie Inc. ABBV inched 0.10% higher to $173.37 Friday, on what proved to be an all-around mixed trading session ...

Buying Nimble Therapeutics represents AbbVie's latest deal to build out a pipeline in the wake of fading sales of its once ...

Shares of AbbVie Inc. oscillated between gains and losses Friday as the company’s latest acquisition drew mixed reactions ...

Friday announced an agreement to acquire Nimble Therapeutics for a cash payment of $200 million at closing, along ...

The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target ...

Most patients with chronic lymphocytic leukemia eventually relapse. A bispecific antibody drug may give them "another can to ...

AbbVie has agreed to buy privately held biotechnology company Nimble Therapeutics for $200 million in cash in a deal that bolsters the biopharmaceutical company's expansive immunology portfolio.

AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. | AbbVie is paying $200 million to snap up Nimble ...

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including a survey on nicotine use in ...

Top Dividend Kings for long-term investing in 2024, including high-yielders and top-gain potentials across various sectors.

AbbVie (ABBV) and Nimble Therapeutics announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical ...